Download Citation
Article Source:
EGFR mutation-guided use of afatinib, erlotinib and gefitinib for advanced non-small-cell lung cancer in Hong Kong – A cost-effectiveness analysis
You JHS,
Cho WCS,
Ming Wk,
Li Yc,
Kwan Ck,
et al.
(2021)
EGFR mutation-guided use of afatinib, erlotinib and gefitinib for advanced non-small-cell lung cancer in Hong Kong – A cost-effectiveness analysis.
PLOS ONE 16(3): e0247860.
https://doi.org/10.1371/journal.pone.0247860